...
首页> 外文期刊>BMC Musculoskeletal Disorders >Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy
【24h】

Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy

机译:利妥昔单抗对2例铁蛋白缺乏的肌营养不良患者的疗效

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The administration of rituximab (RTX) in vivo results in B-cell depletion, but evidence for multiple mechanisms of action have been reported. Surprisingly, B cell depletion produced a response in patients with polymyositis, which is characterized as a T cell-mediated autoimmune disorder with biopsy findings similar to Miyoshi myopathy (MM). Indeed, in dysferlinopathies, there is evidence of immune system involvement including the presence of muscle inflammation and a down regulation of the complement inhibitory factor, CD55. Methods Two patients were treated with four weekly infusions of RTX 375 mg/m2. To measure the improvement in muscle strength after treatment, the isometric hand grip maximal voluntary contraction (MVC) was measured by load cell four times during treatment, and again after one year. In order to assess the reproducibility of our grip assessment, we determined the hand MVC analysis in 16 healthy subjects. Moreover, we measured the number of B cells present in patients by flow cytometric analysis during the course of treatment. Results The analysis of B cell number during the course of treatment showed that CD20- and CD19-positive cells were depleted to 0-0.01%. The decrease in B cells was followed by an improvement in the mobility of the pelvic and shoulder girdles as shown by the MRC%. The MVC values of both patients began at values lower than normal whereas during treatment patients had improved percentage of muscle strength. The strength peak in both patients coincided with the minimum B cell values. There were no severe adverse events associated with an infusion of RTX. Conclusion We consider the increase in muscle strength observed in both treated patients to be a consequence of their treatment with RTX. To our knowledge, these are the first cases of increased muscle strength in patients with MM. Furthermore, the results of this study indicate that B cell depletion with RTX may be useful in the treatment of patients affected by MM, suggesting a possible role for B cells in the pathophysiology of this muscle disorder.
机译:背景技术体内使用利妥昔单抗(RTX)会导致B细胞耗竭,但已报道了多种作用机制的证据。出人意料的是,B细胞耗竭在多发性肌炎患者中产生了反应,其特征为T细胞介导的自身免疫性疾病,其活检结果类似于三好肌病(MM)。确实,在神经营养不良症中,有免疫系统参与的证据,包括肌肉炎症的存在和补体抑制因子CD55的下调。方法2例患者每周接受四次RTX 375 mg / m2输注治疗。为了测量治疗后肌肉力量的改善,在治疗过程中,测力传感器四次测量等距手的最大自主收缩(MVC),一年后再次测量。为了评估我们握力评估的可重复性,我们确定了16位健康受试者的手MVC分析。此外,我们在治疗过程中通过流式细胞术分析测量了患者体内B细胞的数量。结果在治疗过程中对B细胞数目的分析表明,CD20和CD19阳性细胞被消耗至0-0.01%。 B细胞减少后,骨盆和肩带的活动性改善,如MRC%所示。两名患者的MVC值均始于低于正常值,而在治疗过程中,患者的肌肉力量百分比有所提高。两名患者的强度峰值均与最小B细胞值一致。输注RTX没有严重的不良事件。结论我们认为在两名接受治疗的患者中观察到的肌肉力量增加是他们接受RTX治疗的结果。据我们所知,这是MM患者肌肉力量增加的首例。此外,这项研究的结果表明,RTX清除B细胞可能在治疗受MM影响的患者中有用,这表明B细胞在这种肌肉疾病的病理生理中可能发挥作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号